title: Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding.
authors.affiliation: Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
authors.forename: Narendranath
authors.initials: N
authors.lastname: Epperla
authors.affiliation: Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
authors.forename: Jonathan T
authors.initials: JT
authors.lastname: Kapke
authors.affiliation: Division of Transfusion Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
authors.forename: Matthew
authors.initials: M
authors.lastname: Karafin
authors.affiliation: Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
authors.forename: Kenneth D
authors.initials: KD
authors.lastname: Friedman
authors.affiliation: Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.
authors.forename: Patrick
authors.initials: P
authors.lastname: Foy
mesh_terms: D000328:Adult; D000074322:Antineoplastic Agents, Immunological / Q000008:administration & dosage*; D000068258:Bevacizumab / Q000008:administration & dosage*; D005260:Female; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D000074322:Antineoplastic Agents, Immunological; D000068258:Bevacizumab